Lehrstuhl Biomaterialien, Universitätsstraße 30, Universität Bayreuth, Bayreuth D-95447, Germany.
Biomater Sci. 2015 Mar;3(3):543-51. doi: 10.1039/c4bm00401a. Epub 2015 Jan 13.
Drug delivery systems allow tissue/cell specific targeting of drugs in order to reduce total drug amounts administered to an organism and potential side effects upon systemic drug delivery. Most drug delivery systems are polymer-based, but the number of possible materials is limited since many commercially available polymers induce allergic or inflammatory responses or lack either biodegradability or the necessary stability in vivo. Spider silk proteins represent a new class of (bio)polymers that can be used as drug depots or drug delivery systems. The recombinant spider silk protein eADF4(C16), which can be processed into different morphologies such as particles, films, or hydrogels, has been shown to fulfil most criteria necessary for its use as biomaterial. Further, eADF4(C16) particles have been shown to be well-suited for drug delivery. Here, a new method was established for particle production to reduce particle size and size distribution. Importantly, cellular uptake of these particles was shown to be poor in HeLa cells. Therefore, variants of eADF4(C16) with inversed net charge or incorporated cell penetrating peptides and receptor interacting motifs were tested, showing much better cellular uptake. Interestingly, uptake of all silk variant particles was mainly achieved by clathrin-mediated endocytosis.
药物传递系统允许药物针对组织/细胞进行靶向,以减少给予生物体的总药物量和全身药物递送后的潜在副作用。大多数药物传递系统是基于聚合物的,但由于许多市售聚合物会引起过敏或炎症反应,或者缺乏生物降解性或体内必要的稳定性,因此可能的材料数量有限。蜘蛛丝蛋白代表了一类新型的(生物)聚合物,可作为药物储存库或药物传递系统使用。重组蜘蛛丝蛋白 eADF4(C16) 可以加工成不同的形态,如颗粒、薄膜或水凝胶,已被证明满足作为生物材料使用的大多数必要标准。此外,eADF4(C16) 颗粒已被证明非常适合药物传递。在这里,建立了一种新的颗粒生产方法来减小颗粒尺寸和尺寸分布。重要的是,已经表明这些颗粒在 HeLa 细胞中的细胞摄取能力很差。因此,测试了具有反转净电荷或掺入细胞穿透肽和受体相互作用基序的 eADF4(C16)变体,显示出更好的细胞摄取。有趣的是,所有丝变体颗粒的摄取主要通过网格蛋白介导的内吞作用实现。
Biomater Sci. 2015-1-13
Biomater Sci. 2016-9-20
Biomaterials. 2010-12-24
Macromol Biosci. 2013-7-23
Biomacromolecules. 2011-6-7
Biomaterials. 2011-11-9
J Control Release. 2015-9-10
Macromol Biosci. 2010-9-9
Adv Exp Med Biol. 2019
Adv Healthc Mater. 2023-4
Nanoscale Adv. 2019-1-14
Front Bioeng Biotechnol. 2022-8-9
Polymers (Basel). 2021-11-29
Cancers (Basel). 2021-10-27
Polymers (Basel). 2021-11-3
Adv Drug Deliv Rev. 2020
Int J Nanomedicine. 2019-8-26